Stock Traders Buy High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw unusually large options trading activity on Tuesday. Investors acquired 18,509 call options on the company. This represents an increase of 190% compared to the average daily volume of 6,379 call options.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review extended: The FDA moved deramiocel’s PDUFA target action date to November 22, 2026, following Capricor’s submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication. The extension gives the agency more time to evaluate the application and gives Capricor an opportunity to address outstanding issues. Capricor FDA review extension
• Positive Sentiment: Analyst upgrade: Oppenheimer upgraded CAPR from “market perform” to “outperform,” citing optimism that deramiocel could ultimately be approved. The upgrade provided a bullish counterpoint to the recent concerns surrounding the therapy’s review. Oppenheimer CAPR upgrade
• Neutral Sentiment: Decision delayed, not rejected: The three-month FDA extension is not an approval or a rejection. It prolongs the regulatory catalyst and may reflect the agency’s need to review new clinical analyses, leaving the timing and probability of approval uncertain. Reuters report on FDA extension
• Negative Sentiment: Securities litigation intensifies: Several law firms are publicizing a shareholder class action covering purchases from December 17, 2025, through July 26, 2026. The complaints allege misleading disclosures involving deramiocel, the HOPE-3 statistical analysis plan, FDA compliance and clinical-data integrity. These are allegations, not established findings, but the litigation adds reputational, financial and regulatory risk. Investors have until September 28, 2026, to seek lead-plaintiff status. Capricor securities lawsuit

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR traded up $1.39 during midday trading on Tuesday, hitting $8.19. The company had a trading volume of 12,925,237 shares, compared to its average volume of 2,880,456. The company has a market cap of $476.05 million, a price-to-earnings ratio of -3.34 and a beta of 0.54. Capricor Therapeutics has a 12-month low of $2.96 and a 12-month high of $40.37. The company has a fifty day moving average of $15.93 and a two-hundred day moving average of $24.72.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts expect that Capricor Therapeutics will post -1.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

CAPR has been the subject of several research analyst reports. Maxim Group downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Wall Street Zen cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Finally, JonesTrading cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of “Hold” and a consensus target price of $29.15.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 25,000 shares of company stock valued at $759,158. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in Capricor Therapeutics in the 1st quarter worth $44,000. ACT Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $43,000. Allworth Financial LP boosted its stake in shares of Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 3,264 shares during the period. State of Wyoming grew its position in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 557 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.